Alzheimer's Disease (AD)
37
11
12
17
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
2.7%
1 terminated out of 37 trials
94.4%
+7.9% vs benchmark
3%
1 trials in Phase 3/4
24%
4 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 17 completed trials
Clinical Trials (37)
Adapting RDAD for DS
Improvement of Sleep Disorders in Patients With Alzheimer's Disease After Sunlight Exposure Therapy.
Investigating the Effectiveness of Personalized Optimal Gamma Auditory Frequency Stimulation Intervention on Cognitive Function Enhancement
Recombinant Human Serum Albumin in the Treatment of AD (Alzheimer Disease) Exploratory Clinical Trials
The BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's Disease
Blood-based Biomarkers for Alzheimer's Disease at the Primary Care Level.
Effects of Auditory Brain Stimulation by "Pink Noise" on Memory Capacities in Alzheimer's Disease: Proof of Concept Study
Phase 1 Study to Evaluate the Safety and Tolerability of 8M2D in Healthy People and Alzheimer's Patients
δ in Dementia Clinical Trials
Acoustic Stimulation During Sleep: Effects on Memory and p-tau217 in MCI
Evaluation of a Neuropsychological Tool to Assess Temporal Processing Abilities in Alzheimer's Disease
Social-cognitive Functioning: Validation of a New Neuropsychological Test
COGSCREEN II: Early Detection of Cognitive Impairment
Alzheimer's Disease Neuroimaging Initiative 3
Prospective Single-Arm Safety Study of Cervical LVA in AD Patients
Improv Music Therapy for Older Adults
Evaluation of SCALE PET Software for Quantitative Brain PET Analysis in Alzheimer's Disease
Quantification of Hsp90 in the Human Brain
A Biomarker-chip Assay in Preserved Red Blood Cells for the Diagnosis of Alzheimer's Disease
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease